
We collaborate with leading universities, healthcare institutions, biotechnology companies, and research organizations to translate scientific discoveries into clinical programs with real-world therapeutic potential.

Groff Health is advancing the next generation of botanical therapeutics, including psilocybin and other naturally derived compounds. Our scientific approach focuses on creating standardized, pharmaceutical-grade medicines supported by rigorous research.

Groff Health operates a comprehensive regulatory platform supporting research, manufacturing, analytical testing, import, export, and clinical supply. This specialized infrastructure creates significant barriers to entry while accelerating partner programs.

Our multidisciplinary team brings together expertise in pharmaceutical manufacturing, clinical research, regulatory affairs, and operational leadership. This experience enables Groff Health to move promising therapies from concept through clinical development with confidence.

Our platform is designed to support multiple therapeutic candidates across diverse disease areas. By leveraging shared manufacturing, regulatory, and scientific capabilities, Groff Health can efficiently expand its development portfolio.

Groff Health Inc is a DEA-authorized U.S. bulk and dose manufacturer, importer, and exporter with a pre-built and compliant infrastructure to support international controlled substance transactions subject to applicable DEA import and export authorization.
Groff Health is currently raising Series A capital to advance the development of next-generation botanical therapeutics.
Qualified accredited investors are invited to contact our team to learn more about the investment opportunity and receive available company materials..
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.